Abstract
In order to achieve tumor-specific targeting of adeno-associated virus (AAV)-mediated gene expression, the promoter of the glucose transporter isoform 1 (GLUT1) gene was cloned upstream of the enhanced green fluorescence protein (EGFP) and the herpes simplex virus thymidine kinase (HSVtk) gene. FACS analysis performed at 48 h after transient infection with rAAV/cytomegalovirus (CMV)egfp viral particles revealed an increase of fluorescence in all the cell lines tested. However, EGFP expression under control of the GLUT1 promoter element (rAAV/GTI-1.3egfp) was limited to the tumor cells and oncogene-transformed cells. Evidence for phosphorylation of the HSVtk substrates ganciclovir (GCV) and 125I-deoxycytidine was found in all transfected tumor cell lines compared to noninfected controls (HCT116: 111%; MH3924A: 130%; HaCaT-RT3: 257% increase), but not in HaCaT and HUVEC cells. Furthermore, tumor cells and the oncogene-transformed (ras) cell line HaCaT-RT3 showed a GCV-induced reduction in cell number (HCT116: −71%; MH3924A: −43% and HaCaT-RT3: −31%). No statistically relevant cytotoxic effect was observed in HaCaT (6% decrease) and HUVEC cells (2% decrease). Furthermore, a reduction of 3H-thymidine incorporation into the DNA was seen after treatment with GCV (HCT116: 38%; MH3924A: 33% and HaCaT-RT3: 37% decrease). In a therapy study of HSVtk-expressing tumors with GCV, we achieved total tumor remission.
Similar content being viewed by others
References
Colombo BM, Benedetti S, Ottolenghi S, et al. The ‘bystander effect’: association of U-87 cell death with ganciclovir-mediated apoptosis of nearby cells and lack of effect in athymic mice. Hum Gene Ther. 1995;6:763–772.
Moolten FL . Tumor chemosensitivity conferred by inserted herpes virus thymidine kinase genes: paradigm for a prospective cancer control strategy. Cancer Res. 1986;4:5276–5281.
Dachs GU, Dougherty GJ, Startford IJ, et al. Targeting gene therapy to cancer: a review. Oncol Res. 1997;9:313–323.
Anderson LM, Swaminathan S, Zackon I, et al. Adenovirus-mediated tissue-targeted expression of the HSVtk gene for the treatment of breast cancer. Gene Therapy. 1999;6:854–864.
Shirakawa T, Ko SC, Gardner TA, et al. In vivo suppression of osteosarcoma pulmonary metastasis with intravenous osteocalcin promoter-based toxic gene therapy. Cancer Gene Ther. 1998;5:274–280.
Jiang S, Altmann A, Grimm D, et al. Tissue-specific gene expression in medullary thyroid carcinoma cells employing calcitonin regulatory elements and AAV vectors. Cancer Gene Ther. 2001;8:469–472.
Harris JD, Gutierrez AA, Hurst HC, et al. Gene therapy for cancer using tumor-specific prodrug activation. Gene Therapy. 1994;1:170–175.
Ring CJA, Harris JD, Hurst HC, et al. Suicide gene expression induced in tumor cells transduced with recombinant adenoviral, retroviral and plasmid vectors containing the ERBB2 promoter. Gene Therapy. 1996;3:1094–1103.
Ring CJA, Blouin P, Martin LA, et al. Use of transcriptional regulatory elements of the MUC1 and ERBB2 genes to drive tumor-selective expression of a prodrug activating enzyme. Gene Therapy. 1997;4:1045–1052.
Majumdar AS, Hughes DE, Lichtsteiner SP, et al. The telomerase reverse transcriptase promoter drives efficacious tumor suicide gene therapy while preventing hepatoxicity encountered with constitutive promoters. Gene Therapy. 2001;8:568–578.
Lipinski KS, Djeha HD, Ismail T, et al. High-level, β-catenin/TCF-dependent transgene expression in secondary colorectal cancer tissue. Mol Ther. 2001;4:365–371.
Warburg O . Biochem. Z. 1923;142:317.
Flier JS, Mueckler MM, Usher P, et al. Elevated levels of glucose transport and transporter messenger RNA are induced by ras or src oncogenes. Science. 1987;235:1492–1495.
Hiraki Y, deHerreros AG, Birnbaum MJ . Transformation stimulates glucose transporter gene expression in the absence of protein kinase C. Proc Natl Acad Sci USA. 1989;86:8252–8256.
Godwin AK, Lieberman MW . Elevation of glucose transporter, c-myc and transin RNA levels by Ha-rasT24 is independent of its effect on the cell cycle. Mol Carcinog. 1991;4:275–285.
White MK, Weber MJ . Transformation by the src oncogene alters glucose transport into rat and chicken cells by different mechanisms. Mol Cell Biol. 1988;8:138–144.
White MK, Weber MJ . The src oncogene can regulate a human glucose transporter expressed in chicken embryo fibro blasts. Mol Cell Biol. 1990;10:301–306.
Sistonen L, Hölttä E, Mäkelä TP, et al. The cellular response to induction of the p21c-Ha-ras oncoprotein includes stimulation of jun gene expression. EMBO J. 1989;9:815–822.
Birnbaum MJ, Haspel HC, Rosen OM . Transformation of rat fibroblasts by FSV rapidly increases glucose transporter gene transcription. Science. 1987;235:1495–1498.
Shawver LK, Olson SA, White MK, et al. Degradation and biosynthesis of the glucose transporter protein in chicken embryo fibroblasts transformed by the src oncogene. Mol Cell Biol. 1987;7:2112–2118.
Godwin AK, Lieberman MW . Early and late responses to induction of ras T24 expression in Rat-1 cells. Oncogene. 1990;5:1231–1241.
Nishioka T, Oda Y, Seino Y, et al. Distribution of the glucose transporters in human brain tumors. Cancer Res. 1992;52:3972–3979.
Yamamoto T, Seino Y, Fukumoto H, et al. Over-expression of facilitative glucose transporter genes in human cancer. Biochem. Biophys Res Commun. 1990;170:223–230.
Mueckler M . Facilitative glucose transporters. Eur J Biochem. 1994;219:713–725.
Murakami T, Nishiyama T, Shirotani T, et al. Identification of two enhancer elements in the gene encoding the type 1 glucose transporter from the mouse which are responsive to serum, growth factor, and oncogenes. J Biol Chem. 1992;267:9300–9306.
Todaka M, Nishiyama T, Murakami T, et al. The role of insulin in activation of two enhancers in the mouse GLUT1 gene. J Biol Chem. 1994;269:29265–29270.
Flotte TR, Carter BJ . Adeno-associated virus vectors for gene therapy. Methods Enzymol. 1998;292:717–732.
Ponnazhagan S, Curiel DT, Shaw DR, et al. Adeno-associated virus for cancer gene therapy. Cancer Res. 2001;615:6313–6321.
Aitken ML, Moss RB, Waltz DA, et al. A phase I study of aerosolized administration of tgAAVCF to cystic fibrosis subjects with mild lung disease. Hum Gene Ther. 2001;12:1907–1916.
Fusenig NE, Boukamp P . Multiple stages and genetic alterations in immortalization, malignant transformation, and tumor progression of human skin keratinocytes. Mol Carcinog. 1998;23:144–158.
Boukamp P, Petrusevska RT, Breitkreutz D, et al. Normal keratinization in a spontaneously immortalized aneuploid human keratinocyte cell line. J Cell Biol. 1988;106:761–771.
Haberkorn U, Khazaie K, Morr I, et al. Ganciclovir uptake in human mammary carcinoma cells expressing herpes simplex virus thymidine kinase. J Nucl Med Biol. 1998;25:367–673.
Salvetti A, Oreve S, Chadeuf G, et al. Factors influencing recombinant adeno-associated virus production. Hum Gene Ther. 1998;9:695–706.
Zolotukhin S, Potter M, Hauswirth WW, et al. A ‘humanized’ green fluorescent protein cDNA adapted for high-level expression in mammalian cells. J Virol. 1996;70:4646–4654.
Grimm D, Kern A, Rittner K, et al. Novel tools for production and purification of recombinant adenoassociated virus vectors. Hum Gene Ther. 1998;9:2745–2760.
Haberkorn U, Altmann A, Morr I, et al. Monitoring gene therapy with herpes simplex virus thymidine kinase in hepatoma cells: uptake of specific substrates. J Nucl Med. 1997;38:287–294.
Bi WL, Parysk LM, Warnick R, et al. In vitro evidence that metabolic cooperation is responsible for the bystander effect observed with HSV-tk retroviral gene therapy. Hum Gene Ther. 1993;4:725–731.
Nottebrock H, Then R . Thymidine concentrations in serum and urine of different animal species and man. Biochem Pharmacol. 1977;26:2175–2179.
Haberkorn U, Bellemann ME, Gerlach L, et al. Uncoupling of 2-fluoro-2-deoxyglucose transport and phosphorylation in rat hepatoma during gene therapy with HSV thymidine kinase. Gene Therapy. 1998;5:880–887.
Acknowledgements
We thank M Mahmut, I Morr and I Preugschat-Gumprecht for their technical help. We also thank U Schierbaum and K Leotta for their help in animal experiments. Supported by the Forschungsförderung of the University of Heidelberg and the Tumorzentrum Heidelberg-Mannheim.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Sieger, S., Jiang, S., Kleinschmidt, J. et al. Tumor-specific gene expression using regulatory elements of the glucose transporter isoform 1 gene. Cancer Gene Ther 11, 41–51 (2004). https://doi.org/10.1038/sj.cgt.7700654
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.cgt.7700654
- Springer Nature America, Inc.
Keywords
This article is cited by
-
Molecular imaging of tumor metabolism and apoptosis
Oncogene (2011)
-
Treatment of human disease by adeno-associated viral gene transfer
Human Genetics (2006)
-
Evaluation of Firefly Luciferase Bioluminescence Mediated Photodynamic Toxicity in Cancer Cells
Molecular Imaging and Biology (2006)
-
Adeno-associated virus vectors: potential applications for cancer gene therapy
Cancer Gene Therapy (2005)